All In Biotech

Drug Trial Radar · NCT04415918

Bezlotoxumab Efficacy and Tolerability in Cancer Patient

Is Bezlotoxumab Effective, Tolerable and Cost Saving in Preventing Recurrent Clostridium Difficile Infections in Patients With Malignancies? An Exploratory Study

Last checked: Nov 20, 2026Latest source record: Jun 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

132

Planned (sponsor's estimate)

Start

Jul 1, 2020

Primary completion

Jul 1, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Cooper Norcross HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigation of efficacy and tolerability of bezlotoxumab in patients with cancer diagnosis in terms of preventing CDI recurrence.

Conditions

  • Clostridium Difficile Infection Recurrence

Interventions

  • Bezlotoxumab InjectionDrug

    A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with recurrent CDIs within 12 weeks of initial cure compared with historical group of patients selected with same inclusion/exclusion criteria (same center within 3 years of the start date of the study).Time frame: 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.